RIBOLIFE-B (06938) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Discuss Final Dividend

Bulletin Express03-12

According to the announcement released by Suzhou Ribo Life Science Co., Ltd. (stock code: 06938, “RIBOLIFE-B”), the Board of Directors will convene on Wednesday, 25 March 2026.

The agenda includes: 1. Reviewing and approving the audited consolidated results for the financial year ended 31 December 2025 and authorising their publication. 2. Considering a recommendation for the payment of a final dividend, if any. 3. Handling other routine corporate matters.

The notice is signed by Chairman Dr. Liang Zicai and dated 12 March 2026 in Hong Kong. The Board currently comprises three executive directors, three non-executive directors and three independent non-executive directors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment